Wendy C. King, PhD1; Jia-Yuh Chen, MS1; Steven H. Belle, PhD1; Anita P. Courcoulas, MD, MPH2; Gregory F. Dakin, MD3; Katherine A. Elder, PhD4,5; David R. Flum, MD, MPH6; Marcelo W. Hinojosa, MD6; James E. Mitchell, MD7; Walter J. Pories, MD8; Bruce M. Wolfe, MD4; Susan Z. Yanovski, MD
Faiza A. Qari, Elaff A. AbuDaood, Tariq A. Nasser
Mishra T, Lakshmi K, Peddi K
Julia Hippisley-Cox, professor of clinical epidemiology and general practice1, Carol Coupland, professor of medical statistics in primary care
Thomas L. Schwenk, MD reviewing Cherkin DC et al. JAMA 2016 Mar 22/29. Goyal M and Haythornthwaite JA. JAMA 2016 Mar 22/29.
Paul S. Mueller, MD, MPH, FACP reviewing Brunström M and Carlberg B. BMJ 2016.
Thomas L. Schwenk, MD reviewing Jin X et al. JAMA 2016 Mar 8.
Allan S. Brett, MD reviewing Snyder PJ et al. N Engl J Med 2016 Feb 18. Orwoll ES. N Engl J Med 2016 Feb 18.
May A. Al-Shahwan, Abdulaziz M. Al-Othman, Nasser M. Al-Daghri, Shaun B. Sabico
The US Food and Drug Administration (FDA) has new data showing that the proton pump inhibitor (PPI) omeprazole (Prilosec/Prilosec OTC) reduces the anti-blood clotting effect of clopidogrel (Plavix) by almost half when these 2 medicines are taken by the same patient. Patients at risk for heart attacks or strokes who use clopidogrel to prevent blood clots will not get the full effect of this medicine if they are also taking omeprazole; therefore, the FDA recommends that the coadministration of omeprazole and clopidogrel be avoided.